BRAF and melanoma: The phase III, IMspire150 or TRILOGY trial evaluated first-line vemurafenib and cobimetinib combined with either atezolizumab or placebo in 514 patients with unresectable stage IIIc–IV BRAF V600-mutated melanoma.